- Several health systems and insurers recently indicated they would not cover or offer Aduhelm, a list that includes the Department of Veterans Affairs, Boston-based Mass General Brigham and eight Blue Cross Blue Shield affiliates.
- Biogen reported $300,000 in Aduhelm sales in its third-quarter financial report released Oct. 20. At a price of $56,000 per year, this is much less than many analysts expected.
- Biogen on Nov. 8 launched an investigation into the death of a 75-year-old patient potentially linked to Aduhelm.
- CMS announced Nov. 13 Medicare Part B premiums and deductibles will see the largest hike in the program’s history next year. The agency said one of the key reasons for this is the potential need to cover the high cost of Aduhelm.
- Biogen said Nov. 15 that its head of research and development, Alfred Sandrock, MD, PhD, will leave the company after 23 years. He is the drugmaker’s top scientist and led its yearslong effort to develop and commercialize Aduhelm.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
